Scotiabank Boosts JAN (NYSE:JAN) Price Target to $33.00

Key Points

• Scotiabank raised JAN’s price target from $31 to $33 while maintaining a “sector outperform” rating, implying approximately 8.4% upside from the referenced share price.
• Analyst sentiment remains broadly positive: JAN has a consensus “Moderate Buy” rating and an average target price of $32.44, with JPMorgan and Morgan Stanley also recently raising their targets.
• JAN’s quarterly revenue rose 45.4% year over year to $216.46 million, beating estimates, but EPS of $0.05 fell well short of the $0.23 consensus. Fiscal 2026 EPS guidance is $0.95–$0.98.

JAN (NYSE:JAN - Get Free Report) had its price target boosted by equities researchers at Scotiabank from $31.00 to $33.00 in a report issued on Thursday, Benzinga reports. The firm currently has a "sector outperform" rating on the stock. Scotiabank's price objective indicates a potential upside of 8.43% from the stock's current price.

JAN has been the subject of a number of other research reports. UBS Group set a $29.00 price target on shares of JAN in a report on Thursday, June 18th. JPMorgan Chase & Co. increased their price objective on JAN from $30.00 to $34.00 and gave the company an "overweight" rating in a report on Tuesday, August 18th. Zacks Research downgraded shares of JAN from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 11th. Wall Street Zen raised shares of JAN from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Morgan Stanley boosted their price objective on JAN from $28.00 to $31.00 and gave the company an "overweight" rating in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.44.

JAN Price Performance

Shares of JAN stock traded down $0.12 on Thursday, hitting $30.43. The stock had a trading volume of 333,708 shares, compared to its average volume of 1,410,172. The business has a 50 day moving average price of $30.48. JAN has a one year low of $22.76 and a one year high of $32.83.

JAN (NYSE:JAN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.18). The company had revenue of $216.46 million for the quarter, compared to the consensus estimate of $203.32 million. The business's revenue for the quarter was up 45.4% compared to the same quarter last year. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. On average, analysts anticipate that JAN will post 0.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On JAN

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Engineers Gate Manager LP acquired a new stake in shares of JAN during the second quarter worth about $15,274,000. Wellington Management Group LLP purchased a new position in shares of JAN during the second quarter worth approximately $8,739,000. WINTON GROUP Ltd acquired a new position in shares of JAN in the 2nd quarter valued at $2,985,000. Readystate Asset Management LP purchased a new stake in JAN in the 2nd quarter valued at $1,724,000. Finally, Greenland Capital Management LP purchased a new position in JAN during the 2nd quarter worth $575,000. Institutional investors and hedge funds own 6.27% of the company's stock.

More JAN News

Here are the key news stories impacting JAN this week:

• Positive Sentiment: Jefferies initiated coverage with a “buy” rating and a $36 price target, implying roughly 18% upside from the referenced $30.44 share price. The call supports the view that JAN’s growth outlook and valuation may be attractive.
• Positive Sentiment: Compass Point began coverage with a “neutral” rating and a $37 price target, implying approximately 22% upside. However, the neutral rating indicates the firm is not yet convinced that the potential upside warrants a stronger bullish stance.
• Neutral Sentiment: Analyst targets are above the current share price, but the target dispersion and mixed ratings suggest uncertainty about JAN’s ability to convert revenue growth into earnings. The company recently reported revenue of $216.5 million, above estimates and up 45.4% year over year, but quarterly EPS of $0.05 missed consensus by $0.18.
• Negative Sentiment: The earnings shortfall remains an overhang. JAN’s fiscal 2026 EPS guidance of $0.95 to $0.98 is broadly in line with the approximately $0.97 analysts expect, leaving limited room for further disappointments or downward revisions.

JAN Company Profile

JanOne Inc is a technology and life sciences company focused on addressing the global opioid crisis. The company's activities include developing and supporting pharmaceutical and other solutions intended to help reduce opioid-related deaths and dependency.

JanOne has also pursued blockchain and financial technology initiatives through its Alt 5 Sigma operations. These activities have included blockchain-based payment, digital asset and financial services solutions designed to help businesses manage transactions and related digital assets.

The company serves markets through its healthcare, technology and financial services initiatives, with an emphasis on solutions that can be applied internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.